Date published: 2026-5-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

EG434726 Inhibitors

EG434726 inhibitors are a specialized class of chemical compounds designed to inhibit the function of the EG434726 protein, which is involved in regulating various cellular processes such as enzymatic activity, protein-protein interactions, and signal transduction. EG434726 plays a key role in facilitating specific biochemical pathways, and its activity is critical for maintaining cellular homeostasis and efficient signal flow within the cell. The inhibitors of EG434726 are designed to bind to specific functional regions of the protein, such as its active site or regulatory domains, thus blocking its interaction with natural substrates or cofactors. This inhibition can be achieved through different mechanisms, including competitive binding, where the inhibitor competes directly with the natural ligand, or non-competitive inhibition, where binding to an allosteric site results in a conformational change that impairs the protein's activity. The design of EG434726 inhibitors aims to achieve high specificity to ensure selective targeting of the protein, minimizing off-target interactions that could affect other related proteins.

The process of designing EG434726 inhibitors involves a detailed understanding of the protein's structure, achieved through techniques such as X-ray crystallography, cryo-electron microscopy (cryo-EM), and nuclear magnetic resonance (NMR) spectroscopy. These structural biology tools help identify key binding pockets and interaction sites that can be effectively targeted by inhibitors. Computational modeling, including molecular docking and molecular dynamics simulations, plays a crucial role in predicting how potential inhibitors will interact with EG434726, allowing for the optimization of their affinity and selectivity. The structure-activity relationship (SAR) studies are then used to guide modifications in the inhibitor's chemical structure, improving properties such as solubility, stability, and binding efficacy. These inhibitors often contain specific functional groups, such as aromatic rings or charged residues, which facilitate their interaction with the target protein through hydrogen bonds, hydrophobic interactions, or van der Waals forces. EG434726 inhibitors can range in complexity from small organic molecules that precisely target specific binding sites to larger, more complex structures that engage multiple domains of the protein. The development of these inhibitors represents a sophisticated interplay of structural insights, synthetic chemistry, and computational techniques to effectively modulate the activity of EG434726 and explore its role in cellular signaling and regulation.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Deferoxamine mesylate

138-14-7sc-203331
sc-203331A
sc-203331B
sc-203331C
sc-203331D
1 g
5 g
10 g
50 g
100 g
$255.00
$1060.00
$2923.00
$4392.00
$8333.00
19
(1)

Iron chelator directly inhibiting Fthl17b by forming stable complexes with ferric iron. Deferoxamine binds extracellularly, preventing iron entry into cells, consequently limiting the availability of iron for Fthl17b-mediated ferric iron binding activity and intracellular sequestering of iron ion in the cytoplasm.

Deferiprone

30652-11-0sc-211220
sc-211220A
1 g
5 g
$124.00
$134.00
5
(1)

Iron chelator influencing Fthl17b indirectly by forming complexes with ferrous iron. Deferiprone modulates iron availability, potentially impacting Fthl17b's ferrous iron binding activity and intracellular sequestering of iron ion.

apo-Transferrin

11096-37-0sc-391092
sc-391092A
sc-391092B
100 mg
500 mg
1 g
$153.00
$469.00
$744.00
1
(0)

Iron-binding glycoprotein competing with Fthl17b for iron binding. Binds ferric iron extracellularly, limiting iron availability for Fthl17b-mediated ferric iron binding activity and intracellular sequestering of iron ion in the cytoplasm.

Gallium(III) nitrate solution, Ga 9-10% w/w

13494-90-1sc-300758
sc-300758A
50 g
250 g
$135.00
$595.00
(0)

Iron analog inhibiting Fthl17b indirectly by disrupting cellular iron homeostasis. Gallium Nitrate interferes with iron-dependent processes, potentially impacting Fthl17b's ferric and ferrous iron binding activities and intracellular sequestering of iron ion in the cytoplasm.

Ciclopirox

29342-05-0sc-217893
25 mg
$207.00
2
(1)

Iron-chelating antifungal impacting Fthl17b indirectly. Ciclopirox chelates iron ions, potentially influencing Fthl17b's ferric and ferrous iron binding activities and intracellular sequestering of iron ion in the cytoplasm by altering iron availability.

Lactoferrin

146897-68-9sc-394420
sc-394420A
sc-394420B
sc-394420C
10 mg
50 mg
100 mg
1 g
$122.00
$408.00
$580.00
$1494.00
(1)

Iron-binding glycoprotein competing with Fthl17b for iron binding. Binds extracellularly, limiting iron availability for Fthl17b-mediated ferric and ferrous iron binding activities and intracellular sequestering of iron ion in the cytoplasm.

Triapine

200933-27-3sc-475303
10 mg
$300.00
(0)

Ribonucleotide reductase inhibitor influencing Fthl17b indirectly by affecting iron-dependent cellular processes. Triapine modulates iron availability, potentially impacting Fthl17b's ferric and ferrous iron binding activities and intracellular sequestering of iron ion in the cytoplasm.

Deferasirox

201530-41-8sc-207509
2.5 mg
$180.00
9
(1)

Iron chelator affecting Fthl17b indirectly by forming complexes with ferric iron. Deferasirox modulates iron availability, potentially impacting Fthl17b's ferric and ferrous iron binding activities and intracellular sequestering of iron ion in the cytoplasm.

2-Picolinic acid

98-98-6sc-238205
sc-238205A
sc-238205B
5 g
100 g
1 kg
$24.00
$54.00
$345.00
(0)

Iron chelator affecting Fthl17b indirectly by forming complexes with iron ions. Picolinic Acid modulates iron availability, potentially impacting Fthl17b's ferric and ferrous iron binding activities and intracellular sequestering of iron ion in the cytoplasm.